[Drugs inhibiting the hepatic fibrogenesis]

Area of Science:

• Hepatology
• Pharmacology
• Biochemistry

Context:

• Chronic liver disease management remains a significant medical challenge.
• Therapeutic strategies focus on causal agent removal or inhibiting hepatic fibrogenesis to prevent cirrhosis.
• Identifying effective antifibrotic agents is crucial for managing progressive liver damage.

Purpose:

• To review and classify compounds exhibiting antifibrotic activity in chronic liver disease.
• To provide a classification model for rapid assessment of antifibrotic agents.
• To categorize drugs based on their primary mechanism of action: direct or indirect fibrogenesis inhibition.

Summary:

• Antifibrotic compounds are classified into two main groups: direct-acting drugs that interfere with collagen metabolism (e.g., interferons, glucocorticoids) and indirect-acting drugs that reduce inflammatory stimuli (e.g., S-adenosylmethionine, ursodeoxycholic acid).
• Some agents, like prostaglandins, exhibit both direct and indirect antifibrotic mechanisms without a predominant action.
• This classification aids in understanding and selecting therapeutic options for inhibiting liver fibrosis progression.

Impact:

• Facilitates a structured approach to selecting antifibrotic therapies for chronic liver conditions.
• Contributes to the development of novel strategies for preventing or reversing liver fibrosis.
• Enhances understanding of drug mechanisms in the context of liver disease progression and treatment.